- NervGen Pharma Corp. (NGEN) is adding an Alzheimer’s disease patient cohort to its phase one clinical trial program
- The clinical trial program is for its lead product, NVG-291
- NVG-291 is a specific and selective protein tyrosine phosphatase sigma inhibitor
- Pending a positive outcome of the results in healthy volunteers, the company intends to add a multi-dose Alzheimer’s disease patient cohort starting in Q1 2022
- NervGen Pharma Corp. opened at C$2.55 per share
NervGen Pharma Corp. (NGEN) is adding an Alzheimer’s disease patient cohort to its phase one clinical trial program.
The clinical trial program is for its lead product, NVG-291, a specific and selective protein tyrosine phosphatase sigma inhibitor.
NervGen President and CEO Paul Brennan said the company is excited about the evolution of its phase one clinical trial program.
“Together with our newly assembled Alzheimer’s disease scientific advisory board, we will continue to progress towards our major anticipated milestones and deliver on our mission of discovering and developing treatments for patients suffering from medical conditions related to nerve damage.”
The company said it remains on track to initiate its phase one program for NVG-291 in healthy volunteers in Q1 2021 – with plans to report top-line results from the single and multiple dose portion of the study in the second half of 2021.
Pending a positive outcome of the results in healthy volunteers, the company intends to add a multi-dose Alzheimer’s disease patient cohort starting in Q1 2022.
The primary objective for including Alzheimer’s disease patients will be to study the safety and pharmacokinetic profile of NVG-291 in both elderly and Alzheimer’s disease patients.
Additionally, the company plans to include various biomarker and cognitive tests to identify early signals of efficacy. Patients enrolled in the study will be dosed for a minimum of 28 days.
NVG-291 is an inhibitor of PTPσ, a promising target for reducing the clinical effects of Alzheimer’s disease. Neuronal damage and chronic inflammation are believed to be major contributors to progressive and permanent cognitive and physical disabilities in Alzheimer’s disease patients.
NervGen believes that inhibiting the activity of PTPσ has the potential to alter Alzheimer’s disease pathology by promoting nerve repair mechanisms such as regeneration, remyelination and plasticity.
NervGen Pharma Corp. opened at C$2.55 per share.
